GILD

$170.390.17%-0.29

Dopo l'orario di chiusura: 170.86+0.47 +0.28%

Gilead Sciences Inc (GILD)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$170.68

Aprire:

$169.85

Volume 24 ore:

6,565,015

Volume relativo:

0.96

Capitalizzazione di mercato:

$211.34B

Reddito:

$29.79B

Utile/perdita netta:

$9.22B

Rapporto P/E:

23.18

EPS:

$7.35

Flusso di cassa netto:

$10.23B

1W Prestazione:

+7.37%

1M Prestazione:

+17.72%

6M Prestazione:

+29.43%

1Y Prestazione:

+42.24%

Intervallo 1D:

$166.38$172.61

Intervallo di 1 settimana:

$156.04$175.65

Portata 52W:

$114.02$175.65

Profilo aziendale di Gilead Sciences Inc (GILD)

Nome

Gilead Sciences Inc

Settore

Healthcare

Industria

Drug Manufacturers - General

Telefono

(650) 574-3000

Indirizzo

333 LAKESIDE DR, FOSTER CITY, CA, USA

Dipendente

17,000

@GileadSciences

Prossima data di guadagno

null

Ultimi documenti SEC

SEC

Discussioni di GILD su X

Confronta GILD con LLY, JNJ, ABBV, MRK, NVS

Azioni	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GILD Gilead Sciences Inc	$211.34B	$30.99B	-$3.86B	$13.78B	$7.35
LLY Lilly Eli Co	$1.26T	$86.46B	$27.58B	$10.37B	$27.78
JNJ Johnson Johnson	$651.30B	$99.34B	$16.10B	$20.59B	$8.63
ABBV Abbvie Inc	$510.48B	$64.39B	$6.31B	$18.21B	$2.03
MRK Merck Co Inc	$366.35B	$66.57B	$3.17B	$16.06B	$3.55
NVS Novartis Ag Adr	$304.99B	$54.66B	$13.58B	$16.05B	$7.02

Gilead Sciences Inc Azioni (GILD) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-07-21	Downgrade	Leerink Partners	Outperform → Market Perform
2026-07-06	Aggiornamento	HSBC Securities	Hold → Buy
2026-05-20	Aggiornamento	Maxim Group	Hold → Buy
2026-03-10	Iniziato	Jefferies	Buy
2026-02-20	Iniziato	Barclays	Equal Weight
2026-02-11	Reiterato	Needham	Buy
2026-01-07	Resumed	UBS	Buy
2025-11-24	Resumed	Truist	Buy
2025-11-13	Iniziato	Scotiabank	Sector Outperform
2025-08-19	Aggiornamento	Daiwa Securities	Neutral → Outperform
2025-08-08	Aggiornamento	Truist	Hold → Buy
2025-07-25	Aggiornamento	Needham	Hold → Buy
2025-04-22	Resumed	Cantor Fitzgerald	Overweight
2025-03-04	Reiterato	Oppenheimer	Outperform
2025-02-18	Aggiornamento	Deutsche Bank	Hold → Buy
2025-02-13	Aggiornamento	DZ Bank	Hold → Buy
2025-01-10	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	Resumed	BofA Securities	Buy
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-11-14	Iniziato	Citigroup	Buy
2024-11-08	Downgrade	Maxim Group	Buy → Hold
2024-10-21	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-10-17	Iniziato	Bernstein	Outperform
2024-10-07	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2024-07-08	Aggiornamento	Raymond James	Mkt Perform → Outperform
2024-05-01	Reiterato	Maxim Group	Buy
2024-04-24	Aggiornamento	HSBC Securities	Reduce → Hold
2024-02-22	Downgrade	Truist	Buy → Hold
2023-11-09	Iniziato	Deutsche Bank	Hold
2023-09-08	Aggiornamento	BofA Securities	Neutral → Buy
2023-09-06	Iniziato	HSBC Securities	Reduce
2023-07-24	Reiterato	Barclays	Equal Weight
2023-05-16	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-04-28	Resumed	Piper Sandler	Overweight
2023-01-03	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	Resumed	BofA Securities	Neutral
2022-12-09	Downgrade	DZ Bank	Buy → Hold
2022-10-31	Aggiornamento	Barclays	Underweight → Equal Weight
2022-10-28	Reiterato	BMO Capital Markets	Market Perform
2022-10-28	Reiterato	Cowen	Outperform
2022-10-28	Reiterato	JP Morgan	Overweight
2022-10-28	Reiterato	Jefferies	Buy
2022-10-28	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-10-28	Reiterato	RBC Capital Mkts	Outperform
2022-10-28	Aggiornamento	Truist	Hold → Buy
2022-10-28	Reiterato	Wells Fargo	Equal Weight
2022-10-04	Aggiornamento	JP Morgan	Neutral → Overweight
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-05-23	Iniziato	SVB Leerink	Mkt Perform
2022-02-28	Downgrade	BMO Capital Markets	Outperform → Market Perform
2022-02-02	Reiterato	BMO Capital Markets	Outperform
2022-02-02	Reiterato	BofA Securities	Neutral
2022-02-02	Reiterato	RBC Capital Mkts	Outperform
2022-02-02	Reiterato	Truist	Hold
2022-02-02	Reiterato	Wells Fargo	Equal Weight
2022-01-28	Aggiornamento	Argus	Hold → Buy
2022-01-06	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	Resumed	Wells Fargo	Equal Weight
2021-12-06	Iniziato	Goldman	Neutral
2021-11-19	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2021-11-19	Resumed	Piper Sandler	Neutral
2021-10-20	Resumed	Cowen	Outperform
2021-07-30	Reiterato	BMO Capital Markets	Market Perform
2021-07-30	Reiterato	RBC Capital Mkts	Outperform
2021-04-01	Aggiornamento	Bernstein	Mkt Perform → Outperform
2021-03-30	Aggiornamento	Redburn	Neutral → Buy
2021-01-19	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	Aggiornamento	Guggenheim	Neutral → Buy
2020-11-03	Resumed	Morgan Stanley	Equal-Weight
2020-10-28	Iniziato	UBS	Neutral
2020-09-30	Resumed	Jefferies	Buy
2020-09-15	Aggiornamento	Maxim Group	Hold → Buy
2020-07-31	Reiterato	Credit Suisse	Neutral
2020-07-31	Reiterato	Morgan Stanley	Equal-Weight
2020-07-31	Reiterato	Piper Sandler	Overweight
2020-07-31	Reiterato	RBC Capital Mkts	Outperform
2020-07-31	Reiterato	SunTrust	Hold
2020-07-31	Reiterato	Wells Fargo	Equal Weight
2020-07-20	Aggiornamento	Credit Suisse	Underperform → Neutral
2020-06-03	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2020-05-26	Aggiornamento	SunTrust	Sell → Hold
2020-05-01	Downgrade	JP Morgan	Overweight → Neutral
2020-05-01	Downgrade	Raymond James	Outperform → Mkt Perform
2020-05-01	Downgrade	SunTrust	Hold → Sell
2020-04-27	Downgrade	UBS	Buy → Neutral
2020-04-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
2020-04-20	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-04-17	Downgrade	CFRA	Hold → Sell

Gilead Sciences Inc Azioni (GILD) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	29,443.00	28,754.00	27,116.00	27,281.00	27,305.00
Cost of revenue USD (M)	6,234.00	6,251.00	6,498.00	5,657.00	6,601.00
Gross profit USD (M)	-	-	20,618.00	21,624.00	20,704.00
Operating expenses USD (M)	19,421.00	27,092.00	13,013.00	14,294.00	10,786.00
Operating income USD (M)	10,022.00	1,662.00	7,605.00	7,330.00	9,918.00
Income before tax USD (M)	9,796.00	690.00	6,859.00	5,814.00	8,278.00
Income tax expense USD (M)	1,286.00	211.00	1,247.00	1,248.00	2,077.00
Net income USD (M)	8,510.00	480.00	5,613.00	4,566.00	6,201.00
Basic EPS USD/shares	6.84	0.38	4.54	3.66	4.96
Diluted EPS USD/shares	6.78	0.38	4.50	3.64	4.93
Basic weighted shares shares (M)	1,244.00	1,247.00	1,248.00	1,255.00	1,256.00
Diluted weighted shares shares (M)	1,255.00	1,255.00	1,258.00	1,262.00	1,262.00
Selling, general and administrative USD (M)	5,774.00	6,091.00	6,090.00	5,673.00	5,246.00

Gilead Sciences Inc Azioni (GILD) insider trading

DANIEL O'DAYOct 30 '26
Director
Transazione
Proposed Sale
Costo
$165.61
#Azioni
45,881
Valore ($)
7,598,352
#Azioni Totale
0
Mercier JohannaOct 15 '26
Chief Comm & Corp Aff Officer
Transazione
Sale
Costo
$156.22
#Azioni
3,000
Valore ($)
468,660
#Azioni Totale
113,684
JOHANNA MERCIEROct 15 '26
Officer
Transazione
Proposed Sale
Costo
$156.22
#Azioni
3,000
Valore ($)
468,660
#Azioni Totale
0
Dickinson Andrew DOct 15 '26
Chief Financial Officer
Transazione
Sale
Costo
$156.22
#Azioni
3,000
Valore ($)
468,660
#Azioni Totale
161,096
ANDREW DICKINSONOct 15 '26
Officer
Transazione
Proposed Sale
Costo
$156.22
#Azioni
3,000
Valore ($)
468,660
#Azioni Totale
0
O'Day Daniel PatrickOct 01 '26
Chairman & CEO
Transazione
Sale
Costo
$147.90
#Azioni
15,000
Valore ($)
2,218,508
#Azioni Totale
566,683
ANDREW DICKINSONSep 15 '26
Officer
Transazione
Proposed Sale
Costo
$145.29
#Azioni
3,000
Valore ($)
435,870
#Azioni Totale
0
Mercier JohannaSep 15 '26
Chief Comm & Corp Aff Officer
Transazione
Sale
Costo
$144.22
#Azioni
3,000
Valore ($)
432,646
#Azioni Totale
116,684
Dickinson Andrew DSep 15 '26
Chief Financial Officer
Transazione
Sale
Costo
$145.29
#Azioni
3,000
Valore ($)
435,870
#Azioni Totale
164,096
JOHANNA MERCIERSep 15 '26
Officer
Transazione
Proposed Sale
Costo
$144.22
#Azioni
3,000
Valore ($)
432,646
#Azioni Totale
0

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
DANIEL O'DAY	Director	Oct 30 '26	Proposed Sale	$165.61	45,881	7,598,352	0
Mercier Johanna	Chief Comm & Corp Aff Officer	Oct 15 '26	Sale	$156.22	3,000	468,660	113,684
JOHANNA MERCIER	Officer	Oct 15 '26	Proposed Sale	$156.22	3,000	468,660	0
Dickinson Andrew D	Chief Financial Officer	Oct 15 '26	Sale	$156.22	3,000	468,660	161,096
ANDREW DICKINSON	Officer	Oct 15 '26	Proposed Sale	$156.22	3,000	468,660	0
O'Day Daniel Patrick	Chairman & CEO	Oct 01 '26	Sale	$147.90	15,000	2,218,508	566,683
ANDREW DICKINSON	Officer	Sep 15 '26	Proposed Sale	$145.29	3,000	435,870	0
Mercier Johanna	Chief Comm & Corp Aff Officer	Sep 15 '26	Sale	$144.22	3,000	432,646	116,684
Dickinson Andrew D	Chief Financial Officer	Sep 15 '26	Sale	$145.29	3,000	435,870	164,096
JOHANNA MERCIER	Officer	Sep 15 '26	Proposed Sale	$144.22	3,000	432,646	0

Gilead Sciences Inc Borsa (GILD) Ultime notizie

Nov 02, 2026

Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today - Benzinga

Nov 02, 2026

Bernstein raises Gilead Sciences stock price target on strong growth - Investing.com

Nov 02, 2026

Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow - Yahoo Finance

Nov 02, 2026